SB-649915

SB-649915 is a drug that was developed by GlaxoSmithKline for the treatment of depression and anxiety. It acts as a serotonin-norepinephrine reuptake inhibitor (SNRI) and 5-HT1A receptor agonist.

Pharmacology

SB-649915 is a potent and selective 5-HT1A receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI). It has been shown to have antidepressant and anxiolytic effects in animal studies.

Clinical trials

SB-649915 has undergone Phase I clinical trials for the treatment of depression and anxiety. However, further development of the drug was discontinued by GlaxoSmithKline for undisclosed reasons.

See also

• Serotonin-norepinephrine reuptake inhibitor
• 5-HT1A receptor

References

SB-649915 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski